Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arena Pharmaceuticals, a developer of oral drugs that target G protein-coupled receptors, has released results of Phase 1 trial evaluating APD811 as a treatment for pulmonary arterial hypertension (PAH).
Subscribe to our email newsletter
The double-blind, randomized and placebo-controlled trial showed dose-proportional pharmacokinetic exposure over the tested dose range.
In the trial, the terminal half-life was approximately 20 hours.
The trial investigated around 32 health volunteers in four cohorts of eight participants each – six randomized to APD811 and two to placebo.
Arena senior vice president and chief medical officer William Shanahan said they are encouraged by the results of this early stage clinical trial that suggest APD811 has the potential for once-daily, oral dosing, and our next step will be to evaluate the safety, tolerability and pharmacokinetics of multiple dosing and the optimal titration schedule in a Phase 1b trial.
"The development of APD811 is the result of Arena’s continuing commitment to advance our diverse research and development pipeline," Shanahan said.